ROSOLOVA, Hana, Milada DOBIASOVA, Vladimír SOŠKA, Vladimir BLAHA, Richard CESKA, Barbora NUSSBAUMEROVA, Terezie PELIKANOVA and Miroslav SOUČEK. Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma. Cor et Vasa. Brno: Česká kardiologická společnost, 2014, vol. 56, No 2, p. "e133-e139", 7 pp. ISSN 0010-8650. Available from: https://dx.doi.org/10.1016/j.crvasa.2014.01.003.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma
Authors ROSOLOVA, Hana (203 Czech Republic), Milada DOBIASOVA (203 Czech Republic), Vladimír SOŠKA (203 Czech Republic, guarantor, belonging to the institution), Vladimir BLAHA (203 Czech Republic), Richard CESKA (203 Czech Republic), Barbora NUSSBAUMEROVA (203 Czech Republic), Terezie PELIKANOVA (203 Czech Republic) and Miroslav SOUČEK (203 Czech Republic, belonging to the institution).
Edition Cor et Vasa, Brno, Česká kardiologická společnost, 2014, 0010-8650.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/14:00075601
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.crvasa.2014.01.003
UT WoS 000409977800008
Keywords in English AIP = log[triglycerides/ HDL-cholesterol]); Atherogenic index of plasma; Combined lipid-modifying therapy; Mixed dyslipidemia
Tags EL OK
Tags Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 27/1/2015 00:40.
Abstract
Purpose: To evaluate the safety and efficacy of combined lipid-modifying agents (statin + fenofibrate) on plasma lipid profile including the atherogenic index of plasma (AIP = log [TG/HDL-C]) in patients at high and very high cardiovascular (CV) risk and mixed dyslipi-demia. Method: A total of 81 patients (53 males, 28 females; 60 ± 9.8 years) were included. Mixed dyslipidemia was defined as having 2 of the following 3 lipid abnormalities: LDL-cholesterol (C) >2.5 mmol/l, HDL-C <1.0 mmol/l in males and <1.3 mmol/l in females, triglycerides (TG) >1.7 mmol/l. Global CV risk was estimated according to the current European guidelines. Management with fenofibrate (160-267 mg) + atorvastatin (10-20 mg) or simvastatin (20- 40 mg) was indicated for 6 months. Males and females were stratified according to the AIP risk categories: AIP <0.11 (low risk), AIP >0.21 (high risk). Results: About 3/4 of high or very high CV risk patients with mixed dyslipidemia (n = 81) suffer from impaired glucose metabolism (44% had type 2 diabetes, 30% had impaired fasting glucose). Six-months combined therapy reduced LDL-C (by 29%) and TG (by 40%) signifi-cantly, but the increase of HDL-C (by 3%) was not significant. There were 47% of males and 57% of females who achieved the target LDL-C levels (<25 or <1.8 mmol/l) and 14% of males and 37% of females who received non-HDL-C <2.6 mmol/l at the end of the study. Also AIP was decreased significantly in majority of the patients (high risk AIP decreased from 87% to 47% of males and from 71% to 25% of females). Conclusion: The combined lipid-modifying therapy led to a significant improvement of the plasma lipid profile, particularly of LDL-C, TG, non-HDL-C and AIP. Atherogenic index of plasma seems to be a very useful marker of CV risk in high and very high CV risk patients with mixed dyslipidemia and glucose abnormalities. More intensive management is needed in those patients.
PrintDisplayed: 18/5/2024 03:12